https://www.israelhealthcarenews.com/article/909019660-brainsway-to-report-first-quarter-2026-financial-results-on-may-13-2026 Israel Healthcare News en PressRelease 2026-04-29T12:00:00+00:00 BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026 https://ml.globenewswire.com/media/ea01c8f7-39be-46d2-a8e0-bc05994f170e/small/brainsway-2021-logo-jpg.jpg https://www.israelhealthcarenews.com/article/909004923-teva-delivers-strong-q1-2026-results-driven-by-innovative-portfolio-growth-and-disciplined-execution Israel Healthcare News en PressRelease 2026-04-29T11:00:00+00:00 Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://www.israelhealthcarenews.com/article/909004885-teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-teva-s-pivot-to-growth-strategy Israel Healthcare News en PressRelease 2026-04-29T10:30:00+00:00 Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://www.israelhealthcarenews.com/article/908732959-silexion-therapeutics-announces-successful-submission-of-phase-2-3-clinical-trial-application-to-germany-s-bfarm-for-sil204-in-kras-driven-locally Israel Healthcare News en PressRelease 2026-04-28T12:45:00+00:00 Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer https://ml-eu.globenewswire.com/media/1070dc42-db79-4712-af48-38ffbdf3b140/small/screenshot-2025-05-13-at-15-29-06-png.png https://www.israelhealthcarenews.com/article/908733220-polypid-to-present-data-from-shield-ii-phase-3-trial-demonstrating-reduced-severity-of-surgical-site-infection-at-surgical-infection-society-2026 Israel Healthcare News en PressRelease 2026-04-28T12:30:00+00:00 PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting https://ml.globenewswire.com/media/43a11cdb-f86b-4d84-bfb0-1870a0a2cb4e/medium/graph-showing-number-of-patients-with-asepsis-score-20-itt-c.png https://www.israelhealthcarenews.com/article/908733751-enlivex-treasury-update-total-rain-holdings-rise-to-78-819-756-062-tokens-as-of-april-27-2026-representing-an-aggregated-value-of-567-million Israel Healthcare News en PressRelease 2026-04-28T12:30:00+00:00 Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million https://ml.globenewswire.com/media/27d4e006-8709-4fd1-8341-5b58381487d4/small/picture1-jpg.jpg https://www.israelhealthcarenews.com/article/908725714-prf-technologies-announces-fda-clearance-of-ind-application-for-ocuring-k-phase-ii-clinical-trial Israel Healthcare News en PressRelease 2026-04-28T12:00:00+00:00 PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial https://ml.globenewswire.com/media/245f4060-af56-451d-a821-f5ee6fb5d2e5/small/picture1-jpg.jpg